← 검색으로

LLY

ELI LILLY & Co

CIK: 0000059478 · Healthcare · Drug Manufacturers - General

기간
948.45 USD
최근 종가 · 사전계산값
PER (TTM)
33.67
PER (Forward)
21.42
EPS (TTM)
-
EPS (Forward)
-
PBR
27.16
시가총액
845.77B
배당수익률
73.00%
베타
0.48
1개월 수익률
-0.71%
3개월 수익률
-10.22%
6개월 수익률
2.77%
1년 수익률
23.01%
2년 수익률
-
5일 평균거래량
3524700
60일 평균거래량
3103352
1년 평균거래량
3730190
5d/60d 거래량 비율
1.14×
60d/1y 거래량 비율
0.83×
변동성(60일, 연환산)
37.11%
BB 스퀴즈 스코어
1.01
SMA50 비율
1.01
SMA200 비율
1.04
RSI (14)
52
20일 수렴도
0.04
52주 최고
1108.09
52주 최저
622.32
고점 대비
-14.41%
저점 대비
52.40%

펀더멘털 갱신: 2026-05-10T09:52:54+00:00 · 시세 갱신: 2026-05-10T06:48:51+00:00

회사 정보

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

섹터
Healthcare
산업
Drug Manufacturers - General
본사
Indianapolis, United States
임직원
50,000명
웹사이트
lilly.com